Bucolome | CAS# 841-73-6 | anti-inflammatory

MedKoo Cat#: 414759 | Name: Bucolome

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Bucolome is a proposed anti-inflammatory agent with possible analgesic properties.

Chemical Structure

Bucolome

CAS#841-73-6

Theoretical Analysis

MedKoo Cat#: 414759

Name: Bucolome

CAS#: 841-73-6

Chemical Formula: C14H22N2O3

Exact Mass: 266.1630

Molecular Weight: 266.34

Elemental Analysis: C, 63.13; H, 8.33; N, 10.52; O, 18.02

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Bucolome; BRN0755320; BRN-0755320; BRN 0755320; Paramidin

IUPAC/Chemical Name

2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-butyl-1-cyclohexyl-

InChi Key

DVEQCIBLXRSYPH-UHFFFAOYSA-N

InChi Code

InChI=1S/C14H22N2O3/c1-2-3-9-11-12(17)15-14(19)16(13(11)18)10-7-5-4-6-8-10/h10-11H,2-9H2,1H3,(H,15,17,19)

SMILES Code

O=C1NC(C(CCCC)C(N1C2CCCCC2)=O)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 266.34 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Ohtani H, Hakoda R, Imaoka A, Akiyoshi T. In silico evaluation of warfarin- bucolome therapy. Biopharm Drug Dispos. 2016 May;37(4):233-42. doi: 10.1002/bdd.2008. PMID: 27214159. 2: Kobayashi M, Takagi M, Fukumoto K, Kato R, Tanaka K, Ueno K. The effect of bucolome, a CYP2C9 inhibitor, on the pharmacokinetics of losartan. Drug Metab Pharmacokinet. 2008;23(2):115-9. doi: 10.2133/dmpk.23.115. PMID: 18445991. 3: Osawa M, Hada N, Matsumoto K, Hasegawa T, Kobayashi D, Morimoto Y, Yamaguchi M, Kanamoto I, Nakagawa T, Sugibayashi K. Usefulness of coadministration of bucolome in warfarin therapy: pharmacokinetic and pharmacodynamic analysis using outpatient prescriptions. Int J Pharm. 2005 Apr 11;293(1-2):43-9. doi: 10.1016/j.ijpharm.2004.12.009. PMID: 15778043. 4: Matsumoto K, Ishida S, Ueno K, Hashimoto H, Takada M, Tanaka K, Kamakura S, Miyatake K, Shibakawa M. The stereoselective effects of bucolome on the pharmacokinetics and pharmacodynamics of racemic warfarin. J Clin Pharmacol. 2001 Apr;41(4):459-64. doi: 10.1177/00912700122010186. PMID: 11304904. 5: Obata H, Watanabe H, Ito M, Hirono S, Hanawa H, Kodama M, Aizawa Y. Effects of combination therapy with warfarin and bucolome for anticoagulation in patients with atrial fibrillation. Circ J. 2011;75(1):201-3. doi: 10.1253/circj.cj-10-0842. Epub 2010 Dec 2. PMID: 21139249. 6: Takamura N, Maruyama T, Chosa E, Kawai K, Tsutsumi Y, Uryu Y, Yamasaki K, Deguchi T, Otagiri M. Bucolome, a potent binding inhibitor for furosemide, alters the pharmacokinetics and diuretic effect of furosemide: potential for use of bucolome to restore diuretic response in nephrotic syndrome. Drug Metab Dispos. 2005 Apr;33(4):596-602. doi: 10.1124/dmd.104.002782. Epub 2005 Jan 7. PMID: 15640375. 7: Kitani K, Kanai S, Nokubo M. The effect of bucolome on the biliary excretion of colchicine in the rat. Tohoku J Exp Med. 1981 Apr;133(4):389-97. doi: 10.1620/tjem.133.389. PMID: 6114580. 8: Semba R, Sato H, Yamamura H. Danger of bucolome in infants with hyperbilirubinaemia. Experimental evidence. Arch Dis Child. 1978 Jun;53(6):503-5. doi: 10.1136/adc.53.6.503. PMID: 28695; PMCID: PMC1544936. 9: Takahashi H, Kashima T, Kimura S, Murata N, Takaba T, Iwade K, Abe T, Tainaka H, Yasumori T, Echizen aH. Pharmacokinetic interaction between warfarin and a uricosuric agent, bucolome: application of In vitro approaches to predicting In vivo reduction of (S)-warfarin clearance. Drug Metab Dispos. 1999 Oct;27(10):1179-86. PMID: 10497145. 10: Hatakeyama Y, Niwano S, Niwano H, Kosukegawa T, Izumi T. Risks and benefits of combined use of bucolome and warfarin in anticoagulation therapy. Int Heart J. 2010;51(6):399-403. doi: 10.1536/ihj.51.399. PMID: 21173515.